Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cg Oncology Inc.
Headquarters: Santa Ana, CA, United States of America
Website: https://www.cgoncology.com/
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Arthur Kuan
Number Of Employees: 113
Enterprise Value: $1,442,359,176
PE Ratio: -16.21
Exchange/Ticker 1: NASDAQ:CGON
Exchange/Ticker 2: N/A
Latest Market Cap: $1,428,304,640
BioCentury | Dec 14, 2024
Finance
Data spells money for a quintet of biotechs
NewAmsterdam’s CETP readout leads to week’s largest follow-on
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Oct 10, 2024
Finance
Down rounds don’t aid post-IPO performance
Neither private down rounds nor IPO step-downs correlate with market performance after IPOs
BioCentury | Jun 29, 2024
Finance
Public Equity Report: Alumis slides after downsized IPO
Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | Jun 14, 2024
Finance
How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D
Weeks after the firm co-led Xaira’s $1B round, Michael Rome looks ahead at ‘big themes’
BioCentury | Feb 22, 2024
Finance
Venture report: Frontier enters clinic with $80M round; ORI’s new $260M fund
Plus: Launches for Sofinnova-backed AI company Bioptimus, peptide start-up Insamo
BioCentury | Feb 21, 2024
Management Tracks
Papa succeeds Miller as Emergent’s CEO
Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
BioCentury | Feb 10, 2024
Finance
Year’s start mostly strong for biotech IPOs
Four of six companies to go public on U.S. exchanges post positive aftermarket moves
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
Items per page:
1 - 10 of 29